Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
21. November 2024 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
THOR Integrated Device
Philips enrolls first patient in U.S. clinical trial for innovative integrated single-device to treat peripheral artery disease
04. November 2024 08:57 ET | Royal Philips
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
15. Oktober 2024 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
15. August 2024 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Logo-uniQure-MS-Word_Orange.jpg
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
20. Juni 2023 07:05 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 20, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study
11. Mai 2023 09:05 ET | Palisade Bio, Inc.
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Company expects enrollment to be...
Compass-logo-RGB-outlines.png
Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer
06. Januar 2023 08:30 ET | Compass Therapeutics
BOSTON, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”; Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...
logo.jpg
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
11. November 2022 10:12 ET | ImCheck Therapeutics SAS
Low-dose ICT01 plus low-dose IL-2 safely and significantly increase the number of activated γ9δ2 T cells, CD8 T cells, and Natural Killer cells in patients with solid tumors Marseille, France,...
Rubius_Logo.jpg
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors
13. Januar 2022 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an...
logo.jpg
ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
12. November 2021 14:20 ET | ImCheck Therapeutics SAS
Oral presentation includes positive safety data across a wide range of ICT01 doses and efficacy data from patients receiving ICT01 plus pembrolizumab confirming durable clinical responses at low ICT01...